Keywords: genentech, xoma, agreement, agreed, develop, jointly, anti-cd11a

Genentech, Xoma Agreement

Article | 13 May 1996

Print This

- Genentech and Xoma have agreed to develop jointly Genentech's anti-CD11a antibody for psoriasis and organ transplant rejection. Under the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in